Citadel Advisors
PGNX

Citadel Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Citadel Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-47,100
Closed -$240K – 10502
2019
Q4 		$240K Sell
47,100
-7,900
-14% -$41.8K ﹤0.01% 7920
2019
Q3 		$278K Buy
55,000
+5,400
+11% +$26.9K ﹤0.01% 7669
2019
Q2 		$306K Sell
49,600
-7,200
-13% -$34.7K ﹤0.01% 7559
2019
Q1 		$264K Buy
56,800
+14,500
+34% +$65.6K ﹤0.01% 7808
2018
Q4 		$178K Sell
42,300
-44,200
-51% -$225K ﹤0.01% 7949
2018
Q3 		$542K Sell
86,500
-25,700
-23% -$197K ﹤0.01% 6571
2018
Q2 		$902K Buy
112,200
+27,500
+32% +$210K ﹤0.01% 5402
2018
Q1 		$632K Sell
84,700
-13,000
-13% -$86.4K ﹤0.01% 5497
2017
Q4 		$581K Buy
97,700
+38,800
+66% +$236K ﹤0.01% 5424
2017
Q3 		$434K Buy
58,900
+32,600
+124% +$207K ﹤0.01% 5526
2017
Q2 		$179K Buy
26,300
+8,600
+49% +$63.5K ﹤0.01% 6636
2017
Q1 		$167K Sell
17,700
-9,800
-36% -$97.8K ﹤0.01% 6643
2016
Q4 		$238K Sell
27,500
-8,700
-24% -$64.3K ﹤0.01% 6031
2016
Q3 		$229K Buy
36,200
+22,300
+160% +$135K ﹤0.01% 6118
2016
Q2 		$59K Sell
13,900
-12,200
-47% -$58.9K ﹤0.01% 6370
2016
Q1 		$114K Buy
26,100
+6,000
+30% +$26.7K ﹤0.01% 5972
2015
Q4 		$123K Buy
20,100
+7,300
+57% +$47.9K ﹤0.01% 6462
2015
Q3 		$73K Sell
12,800
-20,200
-61% -$155K ﹤0.01% 7270
2015
Q2 		$246K Buy
33,000
+16,000
+94% +$96.8K ﹤0.01% 6035
2015
Q1 		$102K Buy
17,000
+10,500
+162% +$66.1K ﹤0.01% 6828
2014
Q4 		$49K Buy
6,500
+6,200
+2,067% +$37.1K ﹤0.01% 7214
2014
Q3 		$2K Sell
300
-9,400
-97% -$46.8K ﹤0.01% 8008
2014
Q2 		$42K Sell
9,700
-8,700
-47% -$33.2K ﹤0.01% 6881
2014
Q1 		$75K Sell
18,400
-54,600
-75% -$279K ﹤0.01% 6436
2013
Q4 		$389K Buy
73,000
+54,700
+299% +$241K ﹤0.01% 4305
2013
Q3 		$92K Buy
18,300
+7,100
+63% +$38.5K ﹤0.01% 5406
2013
Q2 		$50K Buy
+11,200
New +$50.3K ﹤0.01% 5675

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Citadel Advisors's PGNX Position: Q2 2020 in Review

Citadel Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 43,193 shares — an estimated $164K sold.

Citadel Advisors first reported a position in PGNX in Q2 2013 and held it in 25 quarters. The position peaked at $10.3M in Q3 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Citadel Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Citadel Advisors sold 43,193 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $164K.
  • Citadel Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 25 quarters.
  • Citadel Advisors's Progenics Pharmaceuticals Inc position peaked at $10.3M in Q3 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.